A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
Phase 1
Recruiting
- Conditions
- Major Depressive DisorderDepressionHealthy
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Sirtsei Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06570369
- Locations
- ๐บ๐ธ
Alivation Research, Lincoln, Nebraska, United States
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Sirtsei Pharmaceuticals, Inc.
- Target Recruit Count
- 456
- Registration Number
- NCT06254612
- Locations
- ๐บ๐ธ
IMA Clinical Research, Albuquerque, New Mexico, United States
๐บ๐ธSanRo Clinical Research Group, Bryant, Arkansas, United States
๐บ๐ธClinical Innovations, Bellflower, California, United States
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sirtsei Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04510298
- Locations
- ๐บ๐ธ
Collaborative Neuroscience Research, Garden Grove, California, United States
๐บ๐ธHassman Research Institute, Marlton, New Jersey, United States
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Sirtsei Pharmaceuticals, Inc.
- Target Recruit Count
- 319
- Registration Number
- NCT04479852
- Locations
- ๐บ๐ธ
Future Search Trials of Dallas, Dallas, Texas, United States
๐บ๐ธRed Oak Psychiatry Associates, Houston, Texas, United States
๐บ๐ธCore Clinical Research, Everett, Washington, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath